Vaccine to help stop lung cancer drug resistance
Part of Cancer, Lungs & breathing clinical trials.
This early-phase study tests a personalized peptide vaccine designed to help prevent advanced ALK-positive non-small cell lung cancer from developing resistance to current targeted medicines. If you are stable on an ALK drug and don’t already have the specific resistance changes the vaccine targets, it may help your cancer stay controlled longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IV or recurrent non-small cell lung cancer (and it can’t be treated with standard combined “curative” treatments).
- Your tumor tests show ALK rearrangement using one of several test types (FISH, IHC, tissue NGS, or ctDNA testing).
- You are currently taking an ALK targeted drug (crizotinib, ceritinib, alectinib, brigatinib, or lorlatinib) and your disease has been stable for at least 4 months.
- Tests do not show the specific ALK resistance changes that this vaccine is meant to target.
- Your general health allows most daily activity (ECOG performance status 0–1), and you are at least 18 years old.
- You have not had certain recent treatments (chemotherapy within 14 days, or immune therapy within 28 days) and you are not on strong immune-suppressing medicines (like chronic systemic steroids).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ALK201 combined with an immunotherapy drug (ivonescimab) for people with squamous non-small cell lung cancer. The goal is to see if this combination can shrink tumors and is safe.
This trial tests a combination of a personalized peptide vaccine, an immunotherapy drug (PD-1 inhibitor), and radiation for people with advanced non-small cell lung cancer whose disease has gotten worse after at least two standard treatments. It aims to see if this triple therapy can help control the cancer.
This trial tests a personalized mRNA vaccine (made from your own tumor's genetic fingerprint) combined with an immunotherapy drug called adebrelimab. The goal is to see if this combination can help prevent lung cancer from coming back or slow its growth.
This trial tests a combination of a personalized vaccine (made from your tumor's unique markers), a drug that boosts your immune system (PD-1 inhibitor), and targeted radiation for people with advanced lung cancer that has progressed after initial treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This Phase 2 study tests whether ALK-targeted drugs can shrink or control advanced squamous cell cancer that has spread. You may be eligible if your tumor has an ALK gene rearrangement and you have not had prior cancer medicines for this stage.
This study tests a combination of a personalized vaccine made from your tumor's unique markers, a type of immunotherapy (PD-1 inhibitor), and radiation. The goal is to see if this mix can work better for advanced lung cancer that has progressed after initial treatment.
Hear when a new NSCLC Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.